MMPC MICROMouse Program
Please Note: The Pilot & Feasibility Program is now part of the MICROMouse Program
Funds New Collaborative Projects for up to $75,000 per year
The MMPC has set aside an annual budget for small 1 year grants to fund collaborative biomedical
research projects between an MMPC and external investigators, or among MMPCs. The MMPCs provide
tests on a fee for service basis to characterize many of the mouse models of metabolic diseases
that are generated across the country, and therefore are in a unique position to identify
opportunities for new or expanded studies as they arise. The focus will be on 1) projects
that develop or miniaturize phenotyping tests for use in mice; and 2) research-driven projects
that arise from MMPC activities, that combine the interests of two or more investigators, and
that fall outside those research activities currently funded by an MMPC or an investigator’s
established research program.
These funds cannot be used to replace or reduce the fees charged
for requested services of an MMPC.
For instructions on how to submit a MICROMouse Funding Program Application to the MMPC
web portal please click the following link:
MMPC Funding Program Application Submission Basic Training (PDF)
|
|
Research Objectives
Research objectives for MICROMouse projects should reflect the MMPC mission to provide high
quality metabolic studies of mouse models relevant to diabetes and obesity. MICROMouse will
fund high impact technology-, physiology-, or biology-based projects conceived through
interaction with, or between MMPCs. Proposal objectives should take clear advantage of
collaborations with MMPCs to address questions that would be otherwise difficult to answer.
Objectives of the MICROMmouse initiative encompasses pilot and feasibility projects for the
development of new mouse phenotyping tests, as well as research-driven projects that investigate
biology and physiology of disease. MICROMouse proposals that result from user and MMPC interaction
are strongly encouraged, but applications should explicitly address how the proposal is distinct
from the current grant support of principal investigators. Examples of suitable proposals include
but are not limited to:
-
Pilot and feasibility of new phenotyping tests
-
Develop new technologies or miniaturization of existing technologies for use in mice;
-
Develop applications of existing technologies for use in mice;
-
Provide new tests to meet identifiable, outstanding needs necessary to phenotype mouse models of metabolic disease, and;
-
Establish new types of mathematical models, informatics, databases or products that augment the mission of the center.
-
Research-driven projects
-
The pursuit of novel questions formed during routine phenotyping of animals in collaboration with the submitting investigator;
-
Thorough phenotyping of new models that may be important for the study of a variety of diseases, but are outside the scope of the submitting investigator’s funding;
-
To bring together investigators with complimentary mouse models that would not normally interact;
-
Investigation of new molecular targets uncovered by prior MMPC studies. Objectives should be reasonably met within the one year funding period and lead naturally to publication and potential NIH funding.
|
|
Budget
Applicants may request up to $75,000 total costs (direct + indirect costs)
for one year of funding. A narrative justification should be provided only for any
major equipment (cost greater than $5,000) deemed to be necessary for the proposed
project. The number of awards will depend upon the number, quality, duration, and
cost of the applications received. A second year of funding may be available through
a competitive renewal process. Competitive renewal is encouraged especially for
research-driven projects where new and important
objectives that meet the MICROMouse criteria are formed during the first funding
cycle.
Awards will be made as subcontracts from the AMDCC/MMPC Coordinating and
Bioinformatics Unit (CBU) at the Medical College of Georgia and not directly
by the NIH.
|
|
Review
|
Each submitted proposal will be assigned to three reviewers who are either members
of the MMPC External Advisors or external scientists
with expertise in the area of a proposal. The final funding decisions will be made
by the MMPC Steering Committee. Proposals may
be submitted only once for funding consideration unless a revised application is
solicited by the MMPC Steering Committee. Applications for competitive renewal (1
additional year) are encouraged in cases where exemplary progress has been made
and further investigation is warranted.
|
|
Application and Eligibility
The aim of the MICROMouse program is to promote the development of mouse phenotyping
technology and encourage collaborative relationships between the MMPC and its users.
These are 1 year awards intended to fund the development of research
opportunities that may arise during the course of a service provided by the MMPC
or to expand on research interests common to a MMPC user and a MMPC principal investigator.
These awards cannot be used simply to purchase services from an MMPC.
There is no formal deadline associated with MICROMouse applications, but applications
will be reviewed quarterly (March 1, June 1, September 1, December 1) and
so should be submitted accordingly. A letter of intent with a brief (2-3 sentences)
description of the proposed project must be sent to Dr. Richard McIndoe at
rmcindoe@mail.mcg.edu at least two weeks prior to submission of an application.
The brief application should be on the
PHS 398 form, and must be composed of a research plan that includes the following
sections: A. Abstract and Specific Aims, B. Background and Significance, C. Preliminary
Studies, D. Research Design and Methods, E. Explicit description of the collaboration
and contributions of the collaborating investigators. In the case of Pilot and Feasibility
projects, this section should include a brief description of how the test will be made available to MMPC users,
F. Signed letters from any collaborating principal investigators that have not signed the application face
page. G. Literature Cited. H. Detailed Budget. I. Vertebrate Animals (Sections A->E
are limited to 5 pages). Applications should be signed by at least one principal
investigator and an official representing the submitting institution.
NOTE: Applicants should submit one (1) paper copy to the MMPC CBU at the address listed below,
plus submit an electronic version of the application via the MMPC website (PDF format only please).
Eligible Organizations: Public or private institutions in the United States,
such as universities, colleges, hospitals, and laboratories; units of state and
local governments; eligible agencies of the Federal government; faith-based or community-based
organizations; Indian/Native American Tribal Government (Federally Recognized);
Indian/Native American Tribal Government (Other than Federally Recognized); and
Indian/Native American Tribally Designated Organization.
Eligible Project Directors/Principal Investigators: In the collaborative
spirit of the MICROMouse awards, each application must include at least two project
directors/principal investigators, one of whom must be an MMPC investigator. The
application may originate from either the MMPC or the collaborating institution.
Applicants must hold a doctoral level position but young investigators and post-doctoral
fellows are encouraged to apply. Applications from post-doctoral fellows or research
staff must include two letters of recommendation. Individuals from underrepresented
racial and ethnic groups as well as individuals with disabilities are always
encouraged to apply for NIH support.
|
|
Progress Report
|
A progress report is due two months following the completion of the 1 year funding period.
If competitive renewal is sought, the letter of intent and application should be
received for the review cycle prior to end of the projects current funding period.
Application for competitive renewal is not in lieu of a year-end progress report.
|
|
Contact Information
Questions, letters of intent and applications should be sent to the AMDCC/MMPC Coordinating
and Bioinformatics Unit (CBU) (Dr. Richard McIndoe, Director).
Richard McIndoe, Ph.D. (Coordinator)
Coordinating and Bioinformatics Unit
Medical College of Georgia
Center for Biotechnology and Genomic Medicine
1120 15th Street, CA4124
Augusta, GA 30912-4810
Phone: 706-721-3542
Fax: 706-721-3688
|
|
Recipient Abstracts
|
Please click on the links below to view the MMPC MICROMouse Program Recipient Application or
Prior Abstracts from the Pilot & Feasibility Program
Program: Summer Student Opportunities
Year: 2010
- Database mining of phenotype induced by high-fat diets
Gary Cline Yale University (New Haven, CT)
Program: MICROMouse
Year: 2010
- Impact of Bariatric Surgery on Adipose Tissue Inflammation
Alyssa Hasty Vanderbilt University (Nashville, TN)
- REMODELING OF HEPATIC LIPID METABOLISM BY DIETARY METHIONINE RESTRICTION
Thomas W Gettys Pennington Biomedical Research Center (Baton Rouge, LA)
- Role of Melanocortin Signaling in Gastric Bypass-induced Feeding Behavior
Amanda Vanhoose Vanderbilt University (Nashville, TN)
- ß-cell gap-junctional coupling effects on plasma insulin oscillations
Richard Benninger Vanderbilt University (Nashville, TN)
Year: 2009
- A novel AMPK-interacting protein in cardiac metabolism and function
Brian Iritani University of Washington (Seattle, WA)
- Characterization of A New Murine Model of Cardiomyopathy in Type 2 Diabetes
Kevin O'Brien University of Washington (Seattle, WA)
- Effects of acute deletion of selective transcription factors on mouse islets
Craig Nunemaker University of Virginia Health System (Charlottesville, VA)
- Increased risk for diabetes and obesity in offspring of multiparous mice.
Laura Woollett University of Cincinnati (Cincinnati, OH)
- Long Chain Fatty Acids and Mineralocorticoid Receptor Upregulation in a Mouse Model of Diabetic Nephropathy
Bardia Askari University of Washington (Seattle, WA)
Year: 2008
- Characterization of a New Murine Model of Reversal of Diabetic Nephropathy
Charles Alpers University of Washington (Seattle, WA)
- Development of a mouse model of diabetic wound healing
Efi Kokkotou BETH ISRAEL MEDICAL CENTER (Boston, MA)
- Effect of Murine norovirus on the phenotype of LDL Receptor-Deficient mice
Lillian Maggio-Price University of Washington (Seattle, WA)
- Increased risk for diabetes and obesity in offspring of multiparous mice
Laura Woollett University of Cincinnati (Cincinnati, OH)
- Leptin-mediated regulation of spontaneous physical activity in mice
Brent Wisse University of Washington (Seattle, WA)
Program: Pilot & Feasibility
- Circadian Control of Glucose Metabolism and Insulin Action
Carl Johnson Vanderbilt University (Nashville, TN)
- Nucleomic Analysis of Cell-type Specific Gene Expression in Diabetic Mouse Models
Ronald Lynch University of Arizona (Tucson, AZ)
- Live-in gradient layer calorimetry for high throughput metabolic studies of genetically altered mice
Karl Kaiyala University of Washington (Seattle, WA)
- Proteomic analysis of mouse plasma lipoproteins
Sean Davidson University of Cincinnati-Main Campus (Reading, OH)
- Quantifying the reaction rates that affect fatty liver and hepatic function
Michelle Puchowicz Case Western Reserve (Cleveland, OH)
Year: 2007
- Assessment of Bladder Sensory Threshold in Diabetic Mice
Firouz Daneshgari Cleveland Clinic Lerner College of Medicine of CWRU (Cleveland, OH)
- Assessment of Diastolic Heart Function in Diabetic Mice
Elina Minami University of Washington (Seattle, WA)
- Innovations in phenotyping islet function in mouse metabolic disorders
Craig Nunemaker University of Virgina (Charlottesville, VA)
- Lymph Fistula Mouse: A novel model for studying incretin secretion
Phil Howles University of Cincinnati (Cincinnati, OH)
- Monitoring Diabetic Retinopathy Progression in Mice using Hyperspectral Imaging
Karl Zuzak University of Texas at Arlington (Arlington, TX)
- MRI Phenotyping of Murine Diabetic Retinopathy
Bruce Berkowitz Wayne State University (Detroit, MI)
- Noninvasive evaluation of vascular structure and function in mouse models of metabolic disease
Attila Kovacs Washington University (St. Louis, MO)
|
|
|